Malawi vs Mozambique: Average cost of multi drug-resistant tuberculosis treatment
Malawi
1,246 constant 2022 US$
in 2024
Mozambique
1,250 constant 2022 US$
in 2024
Malawi rank
38th
Mozambique rank
37th
Average cost of multi drug-resistant tuberculosis treatment over time
- Malawi
- Mozambique
How they compare
Mozambique currently reports 1,250 constant 2022 US$ against 1,246 constant 2022 US$ in Malawi, a difference of 4 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Mozambique ahead.
Malawi ranks 38th and Mozambique ranks 37th of 92 countries.
Mozambique has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malawi | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,631 constant 2022 US$ | 3,095 constant 2022 US$ | 464 constant 2022 US$ | Mozambique |
| 2020s | 1,785 constant 2022 US$ | 2,464 constant 2022 US$ | 679 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Malawi or Mozambique?
- Mozambique, at 1,250 constant 2022 US$ against 1,246 constant 2022 US$ in Malawi as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Malawi and Mozambique?
- 4 constant 2022 US$, with Mozambique ahead.
- How many years of comparable data are there for Malawi and Mozambique?
- 8 years are reported by both, from 2017 to 2024.
- How do Malawi and Mozambique rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Malawi ranks 38th and Mozambique ranks 37th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.